Cartalax is a short bioregulatory tripeptide studied in laboratory and preclinical models for its influence on fibroblast-associated signaling and tissue maintenance pathways. Fibroblasts are central regulators of extracellular matrix turnover and connective tissue integrity across systems including skin, cartilage, vasculature, and renal tissue. Cartalax is therefore investigated as a research tool for examining how short peptides may modulate proliferation, apoptosis balance, and senescence-linked molecular markers.
In controlled in vitro and animal studies, Cartalax has been evaluated using endpoints such as proliferation markers (e.g., Ki-67), apoptosis-related proteins (including p53-associated signaling), cytokine expression profiles, and matrix-remodeling enzymes. Additional aging-focused research examines how the peptide may influence gene-expression programs associated with cellular senescence and tissue renewal. All findings are investigational and limited to mechanistic laboratory research contexts.
For research use only. Not for human consumption.
References:
Khavinson VK et al., Bull Exp Biol Med, 2002 134(4):356–359
Anisimov VN et al., Mech Ageing Dev, 1997 96(1–3):123–132
Linkova NS et al., Biogerontology, 2014;15(2):161–170
Reviews
There are no reviews yet.